Abstract:Key PointsThe recent failure of novel anti-atherosclerotic therapies in Phase III clinical trials has emphasized the pressing need for robust imaging markers that can reliably assist in the development of drugs for the treatment of atherosclerosis.Conventional methods of imaging atherosclerosis are able to provide quantitative and morphological data, and to date, have principally been used to assess the efficacy of cholesterol-lowering agents.In this article we compare the main imaging modalities used to image atherosclerosis in the clinical trial setting so far, namely quantitative coronary angiography (QCA), carotid intima-media thickness (CIMT), magnetic resonance imaging (MRI), computed tomography (CT) and intravascular ultrasound (IVUS). The ability of these imaging modalities to predict clinical outcomes for a given sample size, and the regulatory considerations pertaining to their use, are also discussed.However, these methods are likely to be inadequate to assess an emerging generation of therapies that modify plaque biology directly. For example, squalene synthase inhibitors, p38 mitogen-activated protein kinase (MAPK) inhibitors, and chemokine (C-C motif) receptor 2 (CCR2) antagonists.We outline how emerging molecular and cellular imaging techniques offer the possibility to quantify changes in biological function at the level of the plaque, even without gross structural change. In this regard, two imaging modalities are discussed in detail: MRI and positron-emission tomography (PET).Currently, no single ideal imaging modality exists. In the future, the careful application of imaging biomarkers will be necessary to ensure that new anti-atherosclerosis therapies are evaluated in the most efficient manner possible.

Targeted Imaging in Atherosclerosis.

Detection and Imaging of Active Substances in Early Atherosclerotic Lesions using Fluorescent Probes

Progress and Perspective of Atherosclerosis-Targeted Molecular Probes: from Precise Imaging to Auxiliary Diagnosis and Treatment

Molecular Imaging and Non-molecular Imaging of Atherosclerotic Plaque Thrombosis

Atherosclerosis imaging on the molecular level

Recent Advances in Molecular Imaging of Atherosclerotic Plaques and Thrombosis

Molecular and Nonmolecular Imaging of Macrophages in Atherosclerosis

Intravascular molecular imaging: translating pathophysiology of atherosclerosis into human disease conditions

Positron Emission Tomography Imaging of Atherosclerosis.

Positron Emission Tomography Imaging of Athero

Novel imaging modalities for the identification of vulnerable plaques

Fluorescent probes for imaging: a focus on atherosclerosis

Carotid Plaque Imaging and the Risk of Atherosclerotic Cardiovascular Disease

Advances of Optical Probes in Atherosclerosis Imaging

Noninvasive Molecular Imaging of Disease Activity in Atherosclerosis

The vascular biology of atherosclerosis and imaging targets

Current Advances in the Diagnostic Imaging of Atherosclerosis: Insights into the Pathophysiology of Vulnerable Plaque

Molecular imaging nanoprobes and their applications in atherosclerosis diagnosis

Intravascular Imaging of Atherosclerosis by Using Engineered Nanoparticles

Uncovering atherosclerotic cardiovascular disease by PET imaging

Form to function: current and future roles for atherosclerosis imaging in drug development